About 1.5 million people died of tuberculosis (TB) in 2017, making it the most lethal infectious disease worldwide. A growing rise in drug-resistant TB is a major obstacle to successfully treating the illness.
Now, researchers at Washington University School of Medicine in St. Louis and Umea University in Sweden have found a compound that prevents and even reverses resistance to isoniazid, the most widely used antibiotic for treating tuberculosis.
The research, published the week of May 6 in Proceedings of the National Academy of Sciences, was conducted in bacteria growing in the lab, setting the stage for future studies in animals and people.
Using the compound in conjunction with isoniazid potentially could restore the antibiotic’s effectiveness in people with drug-resistant tuberculosis. The compound also may bolster the antibiotic’s power to kill TB bacteria – even those sensitive to drugs – which means doctors could start thinking about cutting down the onerous six-month treatment regimen they prescribe today.
“It is very hard for people to comply with such a long regimen,” said co-senior author Christina Stallings, PhD, an associate professor of molecular microbiology at the School of Medicine. “It’s four drugs. They have side effects. It’s no fun. The longer people have to be on antibiotics, the more issues with patient compliance you get, and that can lead to drug resistance and treatment failure. Here, we’ve found a compound that sensitizes bacteria to an antibiotic, prevents drug resistance from arising, and even reverses drug resistance – at least in the lab. If we can turn this compound into a drug for people, it could make our current therapies more effective and be really beneficial for fighting this pandemic.”
Tuberculosis is caused by the bacterium Mycobacterium tuberculosis. Once inside the body, the bacteria morph into a tougher form that can withstand more stress and is harder to kill. Rather than look for new and better antibiotics, Stallings and co-first authors Kelly Flentie, PhD, a former postdoctoral researcher at Washington University, and Gregory Harrison, a graduate student, decided to look for compounds that prevent the bacteria from toughening up. When put in a low-oxygen environment to mimic the stressful conditions TB bacteria encounter inside the body, the bacteria come together and form a thin film called a biofilm that is resilient to not only low-oxygen conditions but also to antibiotics and other stressors.
With the help of co-senior author Fredrik Almqvist, PhD, a professor of chemistry at Umea University, they screened 91 compounds that share a core chemical structure that inhibits biofilms in other bacterial species. The researchers found one compound, called C10, that did not kill the TB bacteria but prevented them from forming a biofilm.
Further experiments showed that blocking biofilm formation with C10 made the bacteria easier to kill with antibiotics and even curbed the development of antibiotic resistance. The researchers needed only a fraction of the amount of isoniazid to kill the TB bacteria when C10 was included than with isoniazid alone. In addition, one out of 1 million TB bacteria spontaneously become resistant to isoniazid when grown under typical laboratory conditions. But when the researchers grew TB bacteria with isoniazid and the compound, the drug-resistant mutant bacteria never arose.
“By combining C10, or something like it, with isoniazid we could enhance the potency of the antibiotic and block the TB bacteria from developing drug resistance,” Stallings said. “That means we might be able to shorten the treatment regimen.”
Most surprisingly, the compound even reversed drug resistance. TB bacteria with mutations in the gene katG can withstand isoniazid treatment. But such bacteria die when treated with isoniazid plus the compound, the researchers discovered. The bacteria had not lost their genetic resistance, but they’d lost the ability to survive when exposed to isoniazid, as long as it was given alongside C10.
“This was a totally unexpected finding,” Stallings said. “We had no idea we would be able to reverse drug resistance. But this could mean that with all those millions of isoniazid-resistant TB cases, if we use something like C10, we could give people the option of using isoniazid again.”
The compound is not ready to be used in people or even tested in animals, Stallings cautioned. This study was conducted on bacteria growing in a lab. The researchers are still figuring out whether the compound is safe and how it might be processed by the body.
“We have this great compound, and we’ve shown that it’s possible to prevent and reverse antibiotic resistance,” Stallings said. “But now we have to either improve on the compound itself so we can start testing it in animals, or figure out how it prevents biofilm formation so we can develop other drugs that target the pathway. We have a new strategy to treat TB, but it’s going to take time before it’s a reality.”
The Latest on: Drug-resistant TB
via Google News
The Latest on: Drug-resistant TB
- Pollution woes: Respiratory issues behind large chunk of deaths in Delhi, says reporton October 7, 2020 at 9:04 pm
In 2018, 23 deaths per day of respiratory diseases, 18 deaths per day of cancer and 11 per day of tuberculosis, finds a report by NGO Praja Foundation.
- Respiratory issues behind large chunk of deaths in Delhion October 7, 2020 at 7:37 pm
The report also stated that percentage of patients diagnosed with Drug-Resistant TB increased by 46 per cent from 1,338 in 2014 to 1,948 in 2018. TB deaths also increased in 2018 in comparison to that ...
- Atomwise Receives a $2.3M Grant to Develop New Therapies for Drug Resistant Malaria and Tuberculosison October 6, 2020 at 6:14 am
The $2.3M in grant funding from the Bill & Melinda Gates Foundation will support the development of multiple global health programs to advance novel antimalarial and anti-tuberculosis small molecule ...
- Tuberculosis, still a threat to Filipino childrenon October 4, 2020 at 8:51 pm
Through the campaign #TBFreePH, the Department of Health (DOH) with the help of the United States Agency International Development (USAID) under TB Innovations and Health Systems Strengthening Project ...
- Q&A: The need for flexibility and innovation in TB care — now more than everon October 1, 2020 at 4:42 am
How has COVID-19 impacted people living with tuberculosis and why might now be the time to innovate for improved patient care? Extensively drug-resistant TB survivor and activist Saurabh Rane explains ...
- P10.6-billion funding gap: Government must increase allocation for TB careon September 28, 2020 at 11:22 pm
For drug-susceptible TB (DSTB), or the type of TB that can be treated by first-line drugs, treatment for an adult may cost P2,300 for six months. For the more potent type called drug-resistant TB ...
- Guv extols Ascent digital project to curb tubercolosison September 28, 2020 at 3:44 am
GOVERNOR Dennis Pineda commended the efforts of Ascent (UnitAid Support Coalition), in collaboration with the Department of Health (DOH) National ...
- Tuberculosis And Covid-19: Fighting A Deadly Syndemicon September 26, 2020 at 4:38 am
Together, Covid-19 and TB pose a deadly, dual threat - a syndemic that feeds on social inequities and poverty. Tremendous catch-up work, advocacy, and funding will be needed, to get back on track, ...
- TB treatment with the help of cell phones pushedon September 24, 2020 at 7:09 pm
Tuberculosis patients, who have developed resistance to anti-tuberculosis drugs or are drug-sensitive, may soon adhere to treatment using a familiar device that is easily accessible to everyone -- ...
- DOH: Proposed 2021 budget for anti-TB program good only for less than half of patients nationwideon September 24, 2020 at 9:12 am
The low budget allocation may also result in higher risks of TB transmission ... some patients may become drug-resistant and may then require stronger antibiotics and a longer treatment period.
via Bing News